<DOC>
	<DOCNO>NCT02811497</DOCNO>
	<brief_summary>This phase 2 study investigational drug , durvalumab give combination azacitidine ( CC-486 ) . The main purpose phase 2 study assess antitumor activity azacitidine combination durvalumab patient microsatellite stable colorectal carcinoma ( MSS-CRC ) , platinum resistant epithelial ovarian cancer type II ( PR-OC ) , estrogen receptor positive HER2 negative breast cancer .</brief_summary>
	<brief_title>Study Azacitidine Durvalumab Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Able provide write informed consent . Age ≥18 year ≥20 year Japanese participant . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy ≥12 week Have histologically cytologicallydocumented , locallyadvanced , metastatic solid malignancy incurable either ( ) fail prior standard therapy , ( b ) standard therapy exist , ( c ) standard therapy consider appropriate patient treat physician . Have one follow advanced ( unresectable and/or metastatic ) solid tumor indication : Microsatellite Stable Colorectal Carcinoma ( MSSCRC ) Platinum Resistant Epithelial Ovarian Cancer Type II ( PROC ) Estrogen Receptor Positive HER2 Negative Breast Cancer ( ER+/HER2 BC ) : The following consideration make regard prior treatment regimen : MSSCRC : must progress intolerant 5FU , irinotecan , oxaliplatin epidermal growth factor receptor ( EGFR ) mAb patient RAS wild type tumor , recurrent/metastatic setting . PROC : must progress least 1 , maximum 2 line cytotoxic agent platinum resistant disease set ER+/HER2 BC : must progress least 2 , maximum 5 line cytotoxic agent recurrent/metastatic setting . Adequate normal organ marrow function Willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . At least one measurable lesion accord RECIST v1.1 . At least one lesion safely accessible biopsy . Be willing provide tissue newly obtain core excisional biopsy tumor lesion . Consent provide archival tumor tissue ( initial subsequent tumor biopsy sample , possible ) correlative biomarker study , available . Female subject childbearing potential1 two negative pregnancy test verify investigator prior start investigational product therapy Females childbearing potential sexually active nonsterilized male partner must agree practice true abstinence use least two effective method contraception study define period . Nonsterilized male sexually active female partner childbearing potential must agree use least two effective method contraception study define period . Involvement plan and/or conduct study previous enrolment present study . Participation another clinical study investigational product last 28 day 5 halflives prior study Day 1 . Concurrent enrolment observational ( noninterventional ) clinical study followup period interventional study allow . Any previous treatment PD1 PDL1 inhibitor , include durvalumab . Prior antiCTLA4 agent allow . Prior therapy Tcell costimulatory agent ( e.g . antiCD137 antibody , antiOX40 antibody ) allow . Prior therapy CC486 , azacitidine , decitabine hypomethylating agent . History another primary malignancy exception . Receipt last dose anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumor embolization , monoclonal antibody , investigational agent ) ≤ 28 day prior first dose study drug ( within 6 week nitrosourea mitomycin C ) . Mean QT interval correct heart rate ( QTc ) ≥470 ms. Current prior use immunosuppressive medication within 28 day first dose durvalumab exception . Any unresolved toxicity CTCAE grade 2 previous anticancer therapy . Any prior Grade ≥3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE &gt; Grade 1 , exception chronic endocrinopathy stable hormone replacement . Active prior document autoimmune disease within past 2 year . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) . History primary immunodeficiency History allogeneic organ transplant History hypersensitivity study drug formulation , include azacitidine , mannitol , durvalumab , constituent , humanize monoclonal antibody Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include patient know evidence acute chronic hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability patient give write informed consent Known history previous clinical diagnosis tuberculosis Receipt live attenuate vaccination within 30 day prior study entry within 30 day investigational product . Female patient pregnant , breastfeed male female patient reproductive potential employ effective method birth control . Irritable bowel syndrome serious gastrointestinal chronic condition associate diarrhea within past 3 year prior start treatment , and/or history prior gastrectomy upper bowel removal , gastrointestinal disorder defect would interfere absorption , distribution , metabolism excretion investigational product and/or predispose patient increase risk gastrointestinal toxicity . Untreated central nervous system ( CNS ) metastatic disease , leptomeningeal disease , cord compression . Patients uncontrolled seizure . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment exception patient adjuvant endocrine therapy history noninvasive breast cancer . Major surgery within 28 day prior Day 1 study still recover prior surgery . Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result . Patients involuntarily incarcerate unable willingly provide consent unable comply protocol procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>